67 related articles for article (PubMed ID: 32356913)
1. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
[TBL] [Abstract][Full Text] [Related]
2. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Gini G; Tani M; Tucci A; Marcheselli L; Cesaretti M; Bellei M; Pascarella A; Ballerini F; Petrini M; Merli F; Olivieri A; Lanza F; Annibali O; Zilioli VR; Liberati AM; Tisi MC; Arcari A; Marino D; Musuraca G; Pavone V; Fabbri A; Pozzi S; Mannina D; Plenteda C; Celli M; Luminari S
Blood; 2023 Oct; 142(17):1438-1447. PubMed ID: 37418685
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib-lenalidomide-rituximab (ZR
Wang Y; Xu J; Li P; Xu Y; Xue H; Liu P
Ann Hematol; 2024 Feb; 103(2):499-510. PubMed ID: 37957370
[TBL] [Abstract][Full Text] [Related]
5. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; García-Domínguez DJ; Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Sánchez-León ML; Silva-Romeiro S; Flores-Campos R; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; Provencio-Pulla M; Sánchez-Beato M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Rueda-Domínguez A; Sánchez-Margalet V; de la Cruz-Merino L
Front Immunol; 2024; 15():1293931. PubMed ID: 38469299
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.
Buckstein R; Kuruvilla J; Chua N; Lee C; Macdonald DA; Al-Tourah AJ; Foo AH; Walsh W; Ivy SP; Crump M; Eisenhauer EA
Leuk Lymphoma; 2011 May; 52(5):833-41. PubMed ID: 21463120
[TBL] [Abstract][Full Text] [Related]
7. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5
Chen X; Zhang Z; Zhang J; Yu Q; Qiu J; Xiao Y; Chen B; Xu P
Transl Cancer Res; 2024 Feb; 13(2):1188-1195. PubMed ID: 38482415
[TBL] [Abstract][Full Text] [Related]
8. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Qualls DA; Lambert N; Caimi PF; Merrill M; Pullarkat P; Godby RC; Bond DA; Wehmeyer GT; Romancik J; Amoozgar B; Leslie L; Nastoupil LJ; Crombie JL; Abramson JS; Khurana A; Nowakowski GS; Maddocks K; Rutherford SC; Kahl B; Okwali M; Buege MJ; Seshan V; Batlevi CL; Salles G
Blood; 2023 Dec; 142(26):2327-2331. PubMed ID: 37738563
[TBL] [Abstract][Full Text] [Related]
9. Tribulations of trials in aggressive lymphoma.
Barraclough A; Hawkes EA
Blood; 2023 Dec; 142(26):2232-2234. PubMed ID: 38153771
[No Abstract] [Full Text] [Related]
10. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
11. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
12. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
Lue JK; O'Connor OA
Lancet Haematol; 2020 Nov; 7(11):e838-e850. PubMed ID: 33091357
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Hou K; Yu Z; Jia Y; Fang H; Shao S; Huang L; Feng Y
Crit Rev Oncol Hematol; 2020 Aug; 152():103010. PubMed ID: 32540781
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
Strati P; Jain P; Johnson RJ; Forbes S; Feng L; Samaniego F; Rodriguez MA; Fayad LE; Hagemeister F; Westin J; Wang M; Neelapu SS; Nastoupil LJ; Fowler NH
Blood; 2021 Feb; 137(8):1124-1129. PubMed ID: 32932518
[No Abstract] [Full Text] [Related]
15. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
[TBL] [Abstract][Full Text] [Related]
16. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM; Calimeri T; Ponzoni M; Curnis F; Conte GM; Scarano E; Rrapaj E; De Lorenzo D; Cattaneo D; Fallanca F; Nonis A; Foppoli M; Lopedote P; Citterio G; Politi LS; Sassone M; Angelillo P; Guggiari E; Steffanoni S; Tarantino V; Ciceri F; Bordignon C; Anzalone N; Corti A
Blood Adv; 2020 Aug; 4(15):3648-3658. PubMed ID: 32766857
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment.
Piccolomo A; Schifone CP; Strafella V; Specchia G; Musto P; Albano F
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899586
[TBL] [Abstract][Full Text] [Related]
18. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H
Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607
[TBL] [Abstract][Full Text] [Related]
19. A Rare Case Report of Photosensitivity in Non-Hodgkin'S Lymphoma Treated with Lenalidomide.
Soni RK; Supekar BB; Mukhi JI; Singh RP
Indian J Dermatol; 2020; 65(4):333-335. PubMed ID: 32831388
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
